Kaletra Related Clinical Trials
GSK706769/KALETRA Drug-drug Interaction Study [Completed]
Comparison of Liquid Kaletra and Low Dose Kaletra Tablets [Completed]
Lopinavir Capsules to Kaletra or Invirase Tablets [Completed]
KONCERT A Kaletra ONCE Daily Randomised Trial of the Pharmacokinetics, Safety and Efficacy of Twice-daily Versus Once-daily Lopinavir/Ritonavir Tablets Dosed by Weight as Part of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-1 (HIV-1) Infected Children (PENTA 18) [Completed]
Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole [Completed]
The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet [Completed]
Evaluation of Kaletra Therapy Over the Long-term [Completed]
Lopinavir/Ritonavir (Kaletra) PK in Children [Completed]
Metabolic Effects of Switching Kaletra to Boosted Reyataz [Completed]
Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study [Terminated]
Kaletra Monotherapy in HIV/HCV Co-infected Subjects [Completed]
Drug Use Investigation of Kaletra [Completed]
Kaletra and Viread in Antiretroviral Naïve Patients [Terminated]
Special Investigation of Kaletra in Pregnant Women [Completed]
Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin [Recruiting]
Raltegravir Kaletra Pharmacokinetics [Completed]
An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin [Completed]
Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir [Completed]
Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China [Completed]
Kaletra-isentress Treatment Evaluation [Completed]
A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines [Completed]
Safety and Efficacy of Kaletra in ARV Therapy Experienced Patients [Completed]
Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily [Recruiting]
Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy [Completed]
Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa [Completed]
Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients [Completed]
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks [Completed]
Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score [Completed]
ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial [Completed]
Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study) [Terminated]
Pharmacokinetic Study of Two Generic co-Formulations of Lopinavir/Ritonavir for HIV Infected Children (SURF) [Completed]
A Comparison Study of Kaletra Soft-Gel Capsules and Kaletra Tablets in an African American Cohort [Completed]
Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil [Completed]
Pharmacokinetic Interactions Between Buprenorphine and Kaletra (Lopinavir/Ritonavir) [Completed]
Lopinavir (LPV) Dose Reduction [Completed]
Drug Use Investigation of Kaletra Tablets (Once Daily Administration) on Patients With HIV-infection [Completed]
Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB [Recruiting]
MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED) [Terminated]
Ritonavir-boosted Lopinavir Monotherapy [Completed]
Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects [Completed]
Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects. [Completed]
Trial About Hepatic Security of Antiretroviral Treatment Based on Kaletra Versus Nevirapine in co-Infected HIV/HCV Patients [Terminated]
Study on the Effect of Kaletra + Nevirapine as Maintenance Bitherapy Compared to a Triple Therapy Including Kaletra + Analogues in HIV Patients [Completed]
Dose Reduction of Lopinavir in Children [Completed]
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL) [Completed]
Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients [Completed]
Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r [Completed]
Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV [Completed]
Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure [Completed]
A Bioavailability Study of Rifabutin and Lopinavir/Ritonavir in Healthy Adult Subjects [Terminated]
Pharmacokinetics of Generic Lopinavir/Ritonavir in Pregnant Women [Completed]
Analysis of Changes in Adipose Tissue of Patients With Lipoatrophy HIV Infection Treated With Nucleoside Thymidine, After Switching to Monotherapy With Lopinavir / Ritonavir [Terminated]
Kaletra in Combination With Antiretroviral Agents [Active, not recruiting]
Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy [Active, not recruiting]
Pilot Assessment of Lopinavir/Ritonavir and Maraviroc [Terminated]
Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting [Completed]
Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children [Completed]
Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients [Completed]
GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir [Completed]
ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects [Completed]
Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis [Active, not recruiting]
Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC [Completed]
A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment [Completed]
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease [Terminated]
Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects [Completed]
Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects [Completed]
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets) [Completed]
Evaluation of the Public Health Interest of Kaletra: Impact on Resistance to Antiretrovirals (ARVs) [Completed]
Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects [Completed]
Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients [Completed]
Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients [Terminated]
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection [Completed]
Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir) [Completed]
TDM of Generic Lopinavir/Ritonavir 200/50 mg [Completed]
Kaletra Sex/Gender Pharmacokinetics (PK) Study [Completed]
Multicountry, Multicenter Post-Marketing Observational Study of Clinical, Biological and Virological Outcomes, Compliance and Tolerability of Kaletra® in Routine Clinical Use [Completed]
High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease [Recruiting]
BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r) [Terminated]
Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy [Terminated]
Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva [Completed]
Differences in Blood Levels of Lopinavir/Ritonavir in HIV Infected Men and Women [Completed]
Safety and Effectiveness of Lopinavir/Ritonavir in Individuals Who Have Failed Prior HIV Therapy [Completed]
Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma [Withdrawn]
Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens [Completed]
Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma [Terminated]
Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients [Recruiting]
GW873140 In Combination With Kaletra In HIV Infected Subjects [Terminated]
Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL) [Completed]
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens [Completed]
Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding [Completed]
Raltegravir vs. Lopinavir/Ritonavir, Both in Combination With Truvada, in HIV+ Treatment Naive Individuals [Completed]
A Simplified Kaletra® (Lopinavir/Ritonavir)-Based Therapy Versus a Sustiva® (Efavirenz)-Based Standard of Care in Previously Non-Treated HIV-Infected Subjects [Completed]
A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen [Completed]
A Multicentre Trial of Second-line Antiretroviral Treatment Strategies in African Adults Using Atazanavir or Lopinavir/Ritonavir [Withdrawn]
Post-Exposure Prophylaxis in Health Care Workers [Completed]
Drug-Drug Interaction of Lopinavir/Ritonavir on Pitavastatin [Completed]
|